The overall objective of this Program Project Grant is to itdentify and test new ways to prevent, detect, and treat colon cancer through an increased understanding ofthe genetics, cell biology and pathogenesis of this malignancy and its precursor lesion, the adenomatous polyp. Our Program focuses on the definition of the molecular mechanisms that underlie the development ofcolon cancer following mutations in the tumor suppressor adenomatous polyposis coll (APC). Since APC is mutated in up to 85% of colorectal cancers and adenomatous polyps, improved understanding of the molecular alterations that characterize tumors harboring APC mutations could result in the identification of novel strategies for improved diagnosis and treatment of colorectal polyps and cancer. The goals of the present Program are centered on APC and other proteins that help mediate its oncogenic effects. These goals are tested in hypotheses using a variety of experimental approaches that include: 1. Utilizing high-risk, inherited APC gene mutation carriers and families in a novel interventional clinical trial that will test combined inhibition of cyclooxygenases and EGFR, two proteins that we found in the previous funding cycle to mediate the oncogenic effects of mutant APC. 2. Characterizing altered mechanisms associated with the loss of APC function, with a focus on events related to decreased retinoic acid production, excess signaling through EGFR, LEF1, TCF4 and deregulated Wnt signaling. 3. Assessing the role of KRAS as a permissive factor in colon cancer development following APC mutation. 4. Evaluating novel pathways for activation of EGFR mediated by inflammatory lipid mediators, including studies in genetically-altered mice and pre-clinical trials in murine models of colon cancer. These investigations, based on work from the previous cycle, involve carcinogenic cell functions of proliferation, differentiation, apoptosis and inflammation and, as noted, will be tested in a systems biology and translational construct utilizing cell culture, zebrafish, mouse and human models.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA073992-15
Application #
8627120
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (O1))
Program Officer
Malone, Winfred F
Project Start
1998-08-10
Project End
2015-02-28
Budget Start
2014-03-01
Budget End
2015-02-28
Support Year
15
Fiscal Year
2014
Total Cost
$1,899,861
Indirect Cost
$622,647
Name
University of Utah
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
009095365
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
Delker, Don A; McGettigan, Brett M; Kanth, Priyanka et al. (2014) RNA sequencing of sessile serrated colon polyps identifies differentially expressed genes and immunohistochemical markers. PLoS One 9:e88367
Samadder, N Jewel; Curtin, Karen; Tuohy, Thérèse M F et al. (2014) Characteristics of missed or interval colorectal cancer and patient survival: a population-based study. Gastroenterology 146:950-60
Tuohy, Therese M F; Rowe, Kerry G; Mineau, Geraldine P et al. (2014) Risk of colorectal cancer and adenomas in the families of patients with adenomas: a population-based study in Utah. Cancer 120:35-42
Stafforini, Diana M; McIntyre, Thomas M (2013) Determination of phospholipase activity of PAF acetylhydrolase. Free Radic Biol Med 59:100-7
Hammoud, Saher Sue; Cairns, Bradley R; Jones, David A (2013) Epigenetic regulation of colon cancer and intestinal stem cells. Curr Opin Cell Biol 25:177-83
Matsumiya, Tomoh; Xing, Fei; Ebina, Masayuki et al. (2013) Novel role for molecular transporter importin 9 in posttranscriptional regulation of IFN-ýý expression. J Immunol 191:1907-15
Sandoval, Imelda T; Manos, Elizabeth J; Van Wagoner, Ryan M et al. (2013) Juxtaposition of chemical and mutation-induced developmental defects in zebrafish reveal a copper-chelating activity for kalihinol F. Chem Biol 20:753-63
Teixeira-da-Cunha, Mariana G A; Gomes, Rachel N; Roehrs, Nathassia et al. (2013) Bacterial clearance is improved in septic mice by platelet-activating factor-acetylhydrolase (PAF-AH) administration. PLoS One 8:e74567
Xu, Changxin; Reichert, Ethan C; Nakano, Tomoyuki et al. (2013) Deficiency of phospholipase A2 group 7 decreases intestinal polyposis and colon tumorigenesis in Apc(Min/+) mice. Cancer Res 73:2806-16
Jasperson, Kory W; Kanth, Priyanka; Kirchhoff, Anne C et al. (2013) Serrated polyposis: colonic phenotype, extracolonic features, and familial risk in a large cohort. Dis Colon Rectum 56:1211-6

Showing the most recent 10 out of 82 publications